Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma

Journal of Experimental & Clinical Cancer Research

Lai-ping Zhong¹  Shu-fang Jin¹  Zhi-yuan Zhang¹  Yao-yao Tu¹  Wu-tong Ju¹  Hai-long Ma¹  Yong Fu¹  Jiang-Li²  Li-zhen Wang² 

[1]Department of Oral & Maxillofacial-Head & Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine

[2]Department of Oral Pathology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine

关键词: Stathmin;    Mutant p53;    Oncogene;    Oral squamous cell carcinoma;   

DOI  :  10.1186/s13046-017-0575-4

来源: DOAJ

【 摘 要 】

Abstract Background The aim of this study was to investigate the oncogenic function and regulatory mechanism of stathmin in oral squamous cell carcinoma (OSCC). Methods Two-dimensional electrophoresis and liquid chromatography-tandem mass chromatography were applied to screen differentiated proteins during carcinogenesis in OSCC. Cell Counting Kit-8 (CCK-8) assays, colony formation, migration, flow cytometry, immunofluorescence and a xenograft model were used to detect the function of stathmin. The correlation between stathmin and p53 expression was analyzed using immunohistochemistry. Mutant/wild type p53 plasmids and small interfering RNA were used to examine the regulation of stathmin. Chromatin immunoprecipitation assays and luciferase assays were performed to detect the transcriptional activation of stathmin by p53. Results Overexpression of stathmin was screened and confirmed in OSCC patients and cell lines. Silencing expression of stathmin inhibited proliferation, colony formation and migration and promoted apoptosis. Poly ADP ribose polymerase (PARP) and cyclin-dependent kinase 1 (cdc2) were activated after silencing the expression of stathmin. Suppression of tumorigenicity was also confirmed in vivo. Mutant p53 transcriptionally activated the expression of stathmin in HN6 and HN13 cancer cells, but not in HN30 cells harboring wild type p53. Conclusions These results suggest that stathmin acts as an oncogene and is transcriptionally regulated by mutant p53, but not by wild-type p53. Stathmin could be a potential anti-tumor therapeutic target in OSCC.

【 授权许可】

Unknown